A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Intervention/treatment:
ETRASIMOD (APD334)
Medical condition:
CROHN'S DISEASE
Protocol code:
C5041006 (APD334-202)
Control number:
235337
Status:
Closed
Approved:
February 20, 2020
Date Completed:
Trial phase:
Phase 2, Phase 3
For more information:
ClinicalTrials.gov - NCT04173273
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 80 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Pfizer ClinicalTrials.gov Call Center
Organization
Pfizer Inc.
Phone:
1-800-718-1021
Sponsor
ARENA PHARMACEUTICALS INC

Locations

Quebec

Centre for Innovative Medicine - Research Institute of the McGill University Health Centre(Pulmonary
Montreal, Quebec, H4A 3J1
Eye Health MD (Ophthalmology)
Montreal, Quebec, H4P 2S4
McGill University Health Centre - Montreal General Hospital (Electrocardiogram Clinic)
Montreal, Quebec, H3G 1A4
McGill University Health Centre - Montreal General Hospital (Endoscopy Clinic)
Montreal, Quebec, H3G 1A4
McGill University Health Centre - Montreal General Hospital (Pharmacy)
Montreal, Quebec, H3G 1A4
McGill University Health Centre - Montreal General Hospital (Radiology)
Montreal, Quebec, H3G 1A4
McGill University Health Centre - Montreal General Hospital (Research Site)
Montreal, Quebec, H3G 1A4

Results

See the results from the trial NCT04173273. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?